Robert D. Koos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Robert D. Koos has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Armina A. Kazi
Department of Physiology, University of Maryland School of Medicine, Baltimore, Maryland 21201
4 shared publicationsKristin Happ Molitoris
Department of Physiology, University of Maryland School of Medicine, 655 West Baltimore Street, Baltimore, Maryland 21201-1559, USA
3 shared publicationsJenny M. Jones
Department of Physiology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
1 shared publicationMark S. Roberson
Department of Biomedical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York 14853, USA
1 shared publication
Latest Publications
- 27 September 2011
- Published by The Endocrine Society in Endocrinology
- Vol. 152 (12) , 4481-4488
Minireview: Putting Physiology Back into Estrogens' Mechanism of Action
After decades of research, the mechanism by which estrogens stimulate the proliferation of epithelial cells in the endometrium and mammary gland, and in the carcinomas that arise in those tissues, is still not understood. Cells do not proliferate in response to 17β-estradiol (E2) alone, and although it is widely recognized that growth factors play a role in E2's proliferative effect, exactly how they are involved is unclear. It has long been known that the proliferation of endometrial epithelial cells is preceded by dramatic increases in blood flow and microvascular permeability, filling the subepithelial stroma with plasma and the proteins it contains, such as IGF-I, which is known to synergize with E2 in the induction of cell proliferation. The hyperpermeability is caused by vascular endothelial growth factor (VEGF), which is rapidly induced by E2, via the transcription factors hypoxia-inducible factor 1 and estrogen receptor α, in luminal epithelial cells in vivo. As we recently showed, VEGF is also strongly induced in endometrial cancer cells in vitro when excessive degradation of hypoxia-inducible factor 1α, caused by the abnormally high oxygen level to which cultured cells are exposed, is prevented. Putting these facts together, we now propose a new model of E2-induced proliferation in which VEGF-induced vascular hyperpermeability plays an essential role. E2 first induces the expression by endometrial epithelial cells of VEGF, which then acts in a paracrine manner to induce interendothelial cell gaps in subepithelial blood vessels, through which plasma and the proteins therein enter the adjacent stroma. Plasma carries even more E2, which circulates bound to proteins, and IGF-l, which together drive epithelial cells completely through the cell cycle.
- 27 September 2011
- Published by The Endocrine Society in Endocrinology
- Vol. 152 (12) , 4481-4488
Minireview: Putting Physiology Back into Estrogens' Mechanism of Action
After decades of research, the mechanism by which estrogens stimulate the proliferation of epithelial cells in the endometrium and mammary gland, and in the carcinomas that arise in those tissues, is still not understood. Cells do not proliferate in response to 17β-estradiol (E2) alone, and although it is widely recognized that growth factors play a role in E2's proliferative effect, exactly how they are involved is unclear. It has long been known that the proliferation of endometrial epithelial cells is preceded by dramatic increases in blood flow and microvascular permeability, filling the subepithelial stroma with plasma and the proteins it contains, such as IGF-I, which is known to synergize with E2 in the induction of cell proliferation. The hyperpermeability is caused by vascular endothelial growth factor (VEGF), which is rapidly induced by E2, via the transcription factors hypoxia-inducible factor 1 and estrogen receptor α, in luminal epithelial cells in vivo. As we recently showed, VEGF is also strongly induced in endometrial cancer cells in vitro when excessive degradation of hypoxia-inducible factor 1α, caused by the abnormally high oxygen level to which cultured cells are exposed, is prevented. Putting these facts together, we now propose a new model of E2-induced proliferation in which VEGF-induced vascular hyperpermeability plays an essential role. E2 first induces the expression by endometrial epithelial cells of VEGF, which then acts in a paracrine manner to induce interendothelial cell gaps in subepithelial blood vessels, through which plasma and the proteins therein enter the adjacent stroma. Plasma carries even more E2, which circulates bound to proteins, and IGF-l, which together drive epithelial cells completely through the cell cycle.
- Open Access
- 9 October 2009
- Published by The Endocrine Society in Endocrinology
- Vol. 150 (12) , 5405-5414
Inhibition of Oxygen-Induced Hypoxia-Inducible Factor-1α Degradation Unmasks Estradiol Induction of Vascular Endothelial Growth Factor Expression in ECC-1 Cancer Cells in Vitro
Estradiol (E2) rapidly and strongly induces vascular endothelial growth factor (VEGF) transcription in uterine endometrial epithelial cells in vivo. We have shown that this is mediated by both the estrogen receptor-α and hypoxia-inducible factor (HIF)-1α. By contrast, E2 induces little or no VEGF expression in cultured breast or endometrial cancer cells, which lack HIF-1α due to the abnormally high concentration of oxygen (∼20%) to which they are exposed. To test the hypothesis that restoring HIF-1α in cultured cells would restore the ability of E2 to induce VEGF expression, we treated human endometrial cancer cells (ECC-1) with cobalt chloride (CoCl2;100 μm), which prevents oxygen-induced HIF-1α degradation. HIF-1α was absent in untreated ECC-1 cells but detectable by 4 h after treatment with CoCl2 alone, as was a significant increase in VEGF mRNA. E2 plus CoCl2 induced detectable HIF-1α expression at 2 h and an even higher level than that induced by CoCl2 alone at 4 h; this HIF-1α was localized in the nuclei. This was accompanied by increasing VEGF expression, with the increase at 4 h severalfold higher than that induced by CoCl2 alone and was concurrent with recruitment of both HIF-1α and estrogen receptor-α to the VEGF promoter. These results confirm that HIF-1α plays an essential role in E2-induced expression of VEGF. Through the induction of increased microvascular permeability and the consequent exudation of plasma growth factors, VEGF in turn may play an essential role in cancer cell proliferation in vivo.
- 9 October 2009
- Published by The Endocrine Society in Endocrinology
- Vol. 150 (12) , 5405-5414
Open AccessInhibition of Oxygen-Induced Hypoxia-Inducible Factor-1α Degradation Unmasks Estradiol Induction of Vascular Endothelial Growth Factor Expression in ECC-1 Cancer Cells in Vitro
Estradiol (E2) rapidly and strongly induces vascular endothelial growth factor (VEGF) transcription in uterine endometrial epithelial cells in vivo. We have shown that this is mediated by both the estrogen receptor-α and hypoxia-inducible factor (HIF)-1α. By contrast, E2 induces little or no VEGF expression in cultured breast or endometrial cancer cells, which lack HIF-1α due to the abnormally high concentration of oxygen (∼20%) to which they are exposed. To test the hypothesis that restoring HIF-1α in cultured cells would restore the ability of E2 to induce VEGF expression, we treated human endometrial cancer cells (ECC-1) with cobalt chloride (CoCl2;100 μm), which prevents oxygen-induced HIF-1α degradation. HIF-1α was absent in untreated ECC-1 cells but detectable by 4 h after treatment with CoCl2 alone, as was a significant increase in VEGF mRNA. E2 plus CoCl2 induced detectable HIF-1α expression at 2 h and an even higher level than that induced by CoCl2 alone at 4 h; this HIF-1α was localized in the nuclei. This was accompanied by increasing VEGF expression, with the increase at 4 h severalfold higher than that induced by CoCl2 alone and was concurrent with recruitment of both HIF-1α and estrogen receptor-α to the VEGF promoter. These results confirm that HIF-1α plays an essential role in E2-induced expression of VEGF. Through the induction of increased microvascular permeability and the consequent exudation of plasma growth factors, VEGF in turn may play an essential role in cancer cell proliferation in vivo.
- Open Access
- 1 August 2009
- Published by Oxford University Press (OUP) in Biology of Reproduction
- Vol. 81 (2) , 378-387
Estrogen Rapidly Activates the PI3K/AKT Pathway and Hypoxia-Inducible Factor 1 and Induces Vascular Endothelial Growth Factor A Expression in Luminal Epithelial Cells of the Rat Uterus1
We have previously shown that 17beta-estradiol (E2) increases vascular endothelial growth factor A (Vegfa) gene expression in the rat uterus, resultin
- 1 August 2009
- Published by Oxford University Press (OUP) in Biology of Reproduction
- Vol. 81 (2) , 378-387
Open AccessEstrogen Rapidly Activates the PI3K/AKT Pathway and Hypoxia-Inducible Factor 1 and Induces Vascular Endothelial Growth Factor A Expression in Luminal Epithelial Cells of the Rat Uterus1
We have previously shown that 17beta-estradiol (E2) increases vascular endothelial growth factor A (Vegfa) gene expression in the rat uterus, resultin
- 1 May 2008
- Published by Oxford University Press (OUP) in Biology of Reproduction
- Vol. 78 (Suppl_1) , 276
HIF-1's Role in Estrogen-Induced VEGF Expression in the Uterus.
- 1 May 2008
- Published by Oxford University Press (OUP) in Biology of Reproduction
- Vol. 78 (Suppl_1) , 276
HIF-1's Role in Estrogen-Induced VEGF Expression in the Uterus.
- 1 May 2005
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1041 (1) , 233-247
New Insight into the Transcriptional Regulation of Vascular Endothelial Growth Factor Expression in the Endometrium by Estrogen and Relaxin
Abstract: Increased uterine capillary permeability, which can be induced by both estrogen and relaxin, is required for endometrial growth and implantation. This effect is mediated in both cases by estrogen receptors (ERs), via stimulation of vascular endothelial growth factor (VEGF) expression. The sites on the VEGF promoter through which induction occurs, however, are completely unclear. We have used the technique of chromatin immunoprecipitation in vivo to localize the site of ER action and identify other transcription factors that are involved. We have found that ERa associates with Sp1/Sp3 at a GC‐rich region of the promoter. More interesting, however, is the observation that estrogen also induces rapid, transient binding of hypoxia‐inducible factor 1 (HIF‐1), which mediates VEGF transcription in response to hypoxia, to the promoter. The estrogen‐induced HIF‐1 binding closely matches the estrogen‐induced pattern of VEGF expression in the uterus, suggesting that HIF‐1 is involved in that induction, and probably that of many other genes as well (HIF‐1 is now known to regulate the expression of more than 40 genes). It is likely that studies now under way will also link relaxin‐induced VEGF expression to HIF‐1. This is based on the similarities in the effects of the two hormones on VEGF expression and on their shared ability to activate the PI3K and MAPK pathways, both of which can activate HIF‐1.
- 1 May 2005
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1041 (1) , 233-247
New Insight into the Transcriptional Regulation of Vascular Endothelial Growth Factor Expression in the Endometrium by Estrogen and Relaxin
Abstract: Increased uterine capillary permeability, which can be induced by both estrogen and relaxin, is required for endometrial growth and implantation. This effect is mediated in both cases by estrogen receptors (ERs), via stimulation of vascular endothelial growth factor (VEGF) expression. The sites on the VEGF promoter through which induction occurs, however, are completely unclear. We have used the technique of chromatin immunoprecipitation in vivo to localize the site of ER action and identify other transcription factors that are involved. We have found that ERa associates with Sp1/Sp3 at a GC‐rich region of the promoter. More interesting, however, is the observation that estrogen also induces rapid, transient binding of hypoxia‐inducible factor 1 (HIF‐1), which mediates VEGF transcription in response to hypoxia, to the promoter. The estrogen‐induced HIF‐1 binding closely matches the estrogen‐induced pattern of VEGF expression in the uterus, suggesting that HIF‐1 is involved in that induction, and probably that of many other genes as well (HIF‐1 is now known to regulate the expression of more than 40 genes). It is likely that studies now under way will also link relaxin‐induced VEGF expression to HIF‐1. This is based on the similarities in the effects of the two hormones on VEGF expression and on their shared ability to activate the PI3K and MAPK pathways, both of which can activate HIF‐1.